Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.

Background: The treatment landscape for metastatic renal cell carcinoma (mRCC) has significantly evolved in recent years. Without direct comparator trials, factors such as cost effectiveness (CE) are important to guide decision-making.

Objective: To assess the CE of guideline-recommended approved first- and second-line treatment regimens.